标题
C-MET inhibitors for advanced non-small cell lung cancer
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 27, Issue 4, Pages 363-375
出版商
Informa UK Limited
发表日期
2018-04-06
DOI
10.1080/13543784.2018.1462336
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
- (2017) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours
- (2017) Jordi Rodon et al. EUROPEAN JOURNAL OF CANCER
- MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
- (2017) J. Goldman et al. Journal of Thoracic Oncology
- Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
- (2017) Alexander Drilon et al. Journal of Thoracic Oncology
- P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET
- (2017) Lyudmila Bazhenova et al. Journal of Thoracic Oncology
- Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2017) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
- (2017) Natasha B. Leighl et al. Oncotarget
- MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.
- (2017) S. F. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- Abstract 873: A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance
- (2016) Ling Liu et al. CANCER RESEARCH
- A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
- (2016) Lee S. Rosen et al. CLINICAL CANCER RESEARCH
- ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence
- (2016) Jieyi Wang et al. CLINICAL CANCER RESEARCH
- Referral practices of medical oncologists to palliative care for patients with metastatic non-small cell lung cancer (NSCLC).
- (2016) Emily Feld et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
- (2016) Tony Shu Kam Mok et al. Journal of Thoracic Oncology
- Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
- (2016) Joel W Neal et al. LANCET ONCOLOGY
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
- (2016) Sa Ye et al. Scientific Reports
- P7.02 * The clinical potential of ARGX-111, an afucosylated anti-MET antibody, in hematological malignancies and suppression of metastasis
- (2015) V. Hanssens et al. ANNALS OF ONCOLOGY
- A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
- (2015) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract A167: A phase I study of MET TKI SAR125844 in Asian patients (pts) with advanced solid tumors
- (2015) Kohei Shitara et al. MOLECULAR CANCER THERAPEUTICS
- Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF
- (2015) Jong Kyu Woo et al. Oncotarget
- Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC
- (2015) Celina D'Cruz et al. CANCER RESEARCH
- LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
- (2014) L. Liu et al. CLINICAL CANCER RESEARCH
- Reply to A. Soultati et al
- (2014) David Robert Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer
- (2014) C. Egile et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
- (2014) Friedhelm Bladt et al. Cancers
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Abstract C173: Anti-tumor activity of SCH 900105 (AV299), an anti-HGF antibody, in non-small cell lung cancer models
- (2012) K. A. Meetze et al. MOLECULAR CANCER THERAPEUTICS
- Structural insights into Met receptor activation
- (2011) Hartmut H. Niemann EUROPEAN JOURNAL OF CELL BIOLOGY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
- (2010) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
- (2010) Giovanni Pacchiana et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status
- (2010) Takamitsu Onitsuka et al. Journal of Thoracic Oncology
- TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation
- (2010) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Expression and mutational analysis ofMETin human solid cancers
- (2008) Patrick C. Ma et al. GENES CHROMOSOMES & CANCER
- Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation
- (2008) Stéphanie Kermorgant et al. JOURNAL OF CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More